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Background: The current standard of care for men with muscle-invasive bladder cancer is radical
cystoprostatectomy (RCP). One-third of RCP specimens demonstrate incidental prostate cancer, primarily
reported in small series with limited follow-up. The aim of this study is to report mature outcomes,
including patterns of failure and disease-speciﬁc recurrence rates, and survival, for a large cohort of men
with incidental prostate cancer at RCP performed at a tertiary referral center.
Methods: This retrospective study describes cancer control and survival rates for men who underwent
RCP for bladder cancer and were found incidentally to have prostate cancer. Analysis of patient-, tumor-,
and treatment-speciﬁc factors were analyzed for association with disease control and survival endpoints.
Results: Between 2002 and 2010, 94 patients with incidental discovery of prostate cancer postRCP were
identiﬁed for inclusion in this study. Forty-ﬁve patients (45%) underwent RCP for recurrent (rather than
initial presentation of) bladder carcinoma. At a median follow-up of 40.3 months (71.2 months for
survivors; range, 8.9e155.5 months), 42 patients were alive without recurrence and 52 patients had died
(25 associated with disease). The estimated 5-year bladder cancer disease-free, urinary tract malignancy
disease-free, and prostate speciﬁc antigen (PSA) relapse-free survivals were 76% [95% conﬁdence interval
(CI), 65e84%], 64% (52e74%), and 97% (79e100%), respectively. The estimated 5-year urinary tract
malignancy-speciﬁc and overall survivals were 61% (49e71%) and 52% (41e62%), respectively. Univariate
analysis demonstrated associations between pathologic T/N-stage and nodal ratio with bladder cancer
disease-free, urinary tract malignancy disease-speciﬁc, and overall survivals, with patient age at diag-
nosis as an additional adverse factor associated with overall survival. Multivariate analysis conﬁrmed pN-
stage and age as independently associated with worse survival.
Conclusion: For men undergoing RCP for bladder cancer, the present study suggests that incidentally
discovered prostate cancers, irrespective of pathologic stage, Gleason score, or clinical signiﬁcance, do
not impact 5-year disease control or survival outcomes.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Radical cystoprostatectomy (RCP) is currently a standard-of-care
curative-intent management option for patients with muscle-
invasive and/or multiply recurrent urothelial carcinoma of the
bladder.1 With 5-year survival rates of ~50%, the identiﬁcation ofOncology, Carver College of
a City, Iowa, 52242, IA, USA.
(J.M. Watkins).
ciﬁc Prostate Society, Published bincidental prostate cancer within the RCP specimen rarely impacts
management considerations.2 Several single-institution series have
focused on reporting the general incidence and rates of “clinically
signiﬁcant” incidental prostate cancers in RCP specimens, with
variable quality and duration of follow-up;2 however, few series
have reported on long-term disease-speciﬁc survival and patterns
of failure, following resection of both pathologic processes.2,3 The
present investigation seeks to describe disease control and survival
outcomes for patients incidentally diagnosed with prostate cancery Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 4 (2016) 107e112108at the time of RCP for bladder cancer, performed at a high-volume
academic tertiary referral center.
2. Materials and methods
This retrospective study was approved by the Institutional Re-
view Board at the participating institution (University of Iowa
Hospitals and Clinics). Patients eligible for the studywere identiﬁed
from a query of electronic medical records, selecting for patients
diagnosed with prostate cancers at the time of RCP. Patients with
known diagnosis of prostate cancer prior to RCP or RCP performed
for reasons other than bladder cancer were excluded from the
study, as were patients with clinically or radiographically evident
metastatic disease prior to RCP. Patients with insufﬁcient follow-up
(nonmortality early loss to follow-up < 3 months postRCP) were
also excluded. Data were collected from existing databases and
electronic medical records. Data ﬁelds included patient de-
mographics, staging characteristics (for bladder cancer), as well as
tumor and treatment speciﬁc variables. Additionally, timing and
patterns of disease failure (speciﬁc to the type of recurrent disease)
were recorded, as were disease status and survival at previous
follow-up.
Pathologic assessment of the cystoprostatectomy specimen
involved external examination of the specimen, including orien-
tation and identiﬁcation of the distal ureters, as well as specimen
size and weight recording. Of note, urethral and distal urethral
margins are frequently removed before receipt of the specimen for
intraoperative assessment of these margins. The external surface is
examined for gross involvement by tumor and differentially inked
for orientation (i.e., left/right). The specimen is then inﬂated with
and submerged in 10% buffered formalin and allowed to ﬁx over-
night. If the specimen is not amenable to inﬂation (due to disrup-
tion or other irregularity), it may be opened anteriorly, taking care
to avoid the primary tumor location upon opening, and padded
with gauze before formalin ﬁxation, to ensure preservation of the
gross architecture. After ﬁxation, standard sections are taken to
assess margins and staging. Pertinent sections taken for micro-
scopic evaluation include representative sections of tumor foci
including the area of deepest invasion, the closest approach to the
deep margin, and any other margins closely approximated by the
tumor. The relationship with the trigone, ureters, and prostate are
also documented and sampled. Representative sections from
grossly uninvolved areas are taken. The ureters are opened longi-
tudinally to grossly evaluate for the presence of a tumor. After any
pertinent sections are taken to evaluate the relationship the
bladder and/or tumor to the prostate, the prostate is serially
sectioned in a plane perpendicular to the prostatic urethra. Grossly
identiﬁed lesions are sampled. If no lesions are noted grossly,
representative transverse sections are submitted entirely to
represent ~50% of the prostatic tissue including the bases of the
seminal vesicles and the proximal ends of the vasa deferentia. The
distal urethra is submitted entirely by removing it in a cone-shape
and radially sectioning it. Any lymph nodes identiﬁed in associated
adipose tissue are submitted entirely.
“Clinically signiﬁcant” prostate cancers were deﬁned using
established histopathologic factors,2 including any one of the
following: pathologic Gleason score > 6, pelvic lymph node
involvement, invasion of the seminal vesicle(s), or positive surgical
margin(s).
All patients in the study were subject to standard follow-up
procedures. This included urologic oncologist follow-up with
urine cytology and computed tomography (CT) imaging every 3e6
months for 2 years postRCP, then annual follow up with cytology
and imaging upon suspicion. With regard to prostate cancer sur-
veillance, serum prostate speciﬁc antigen (PSA) was followed at thediscretion of the managing urologic oncologist, and/or as coordi-
nated with the patient’s local urologist or primary care physician.
The outcome variables measured in this study included overall
survival (OS), as well as disease-free survival (DFS) and disease
speciﬁc survival (DSS), speciﬁc to each: bladder cancer, genitouri-
nary (GU) tract malignancy, and prostate cancer. Relationships
between patient-, tumor-, and treatment-speciﬁc factors were
analyzed for statistically signiﬁcant associations with these end-
points. OS was measured from date of RCP to previous follow-up or
death. DFS wasmeasured from the date of RCP to the earliest sign of
clinical or radiographic disease recurrence, previous urologic
oncology follow-up, or death, with recurrence and treatment-
associated death scored as events. Speciﬁc to prostate cancer DFS
(i.e., PSA relapse-free survival), patients who had a PSA elevation to
 0.1 were not scored as events. Additionally, PSA relapse-free
survival estimates employed only interval to most recently recor-
ded PSA value. DSS was measured from date of RCP to previous
follow-up or death, with death at time of active disease or from
cancer-speciﬁc intervention scored as events. Patients without
evidence of recurrence within 3 months of death were classiﬁed as
“died of other cause,” and not scored as events for DFS or DSS, with
interval calculated at death. Patients known to have died but who
had been lost to follow-up for > 3monthswere classiﬁed as “died of
indeterminate cause,” andwere not scored as events for DFS or DSS,
with interval calculated at previous urologic oncology clinical
evaluation.
2.1. Statistical analysis
Survival probabilities were estimated and plotted using the
KaplaneMeier method. Estimates along with 95% pointwise con-
ﬁdence intervals were reported. Univariate and multivariate Cox
proportional hazards regression was used to assess the effects of
the clinicopathologic variables on the outcomes of interest. The use
of a stepwise selection procedure, variables signiﬁcantly associated
with each outcome at the univariate level and having < 10%missing
information were considered for inclusion in the multivariate
model. All statistical testing was two-sided and assessed for sig-
niﬁcance at the 5% level using SAS, version 9.4 (SAS Institute, Cary,
NC, USA).
3. Results
Between 2002 and 2010, 307 patients underwent RCP for
bladder cancer, of whom 103 had prostate cancers identiﬁed
(33.6%). Ninety-four patients met criteria and were included in the
present investigation. Reasons for exclusion were: prostate cancer
diagnosis known prior to RCP (n ¼ 7), RCP performed for
nonbladder-cancer etiology (n ¼ 5), metastases identiﬁed prior to
RCP (n ¼ 5), and postRCP follow-up < 3 months and lost to follow-
up (n ¼ 4). Median age was 70 years old (range, 41e85), and 98% of
patients were white (n ¼ 92). Approximately half (45%; n ¼ 42) of
patients had history of prior urothelial carcinoma at the time of
presentation for RCP, including 20 of 27 patients without preRCP
evidence of muscle-invasive disease. The majority of patients (71%;
n ¼ 67) had pathologic or radiographic demonstration of muscle-
invasive or more advanced disease (> cT2 and/or Nþ). Per study
design, no patient was known to have diagnosis of prostate cancer
at time of RCP. Additional demographic and preRCP tumor, staging,
and work-up characteristics are outlined in Table 1.
For RCP, all but two patients underwent open RCP, with the
remaining two performed laparoscopically (without robot assis-
tance). Pathologic details are demonstrated in Table 2. Of note, nine
patients had undergone preoperative (neoadjuvant) chemotherapy
(10%), and 11 patients received postoperative (adjuvant)
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radiation therapy.
For the overall population, at amedian follow-up of 40.3months
(71.2 months for survivors; range, 8.9e155.5 months, with 74%
followed  5 years and 21% followed  8 years), there were a total
of 42 surviving patients (38 without recurrence and 4 recurrent GU
malignancies, all salvaged and without active disease) and 52 had
died (22 with recurrent GU malignancy, 3 from complications of
cancer-directed therapy, 10 of nonGU malignancy cause, and 17 of
indeterminate etiology). For the three patients who died of cancer-
directed therapy, one each experienced fatal postoperative pul-
monary embolism, postoperative aspiration pneumonia, and
retroperitoneal hemorrhage following dilation of nonmalignant
uretero-ileal anastomotic stricture (36 months postRCP). For pa-
tients who died of nonGU malignancy etiology, reasons included:
stroke (n¼ 1), hepatocellular carcinoma (n¼ 1), nonsmall-cell lung
cancer (n ¼ 1), glioblastoma multiforme (n ¼ 1), idiopathic pul-
monary ﬁbrosis (n ¼ 1), end-stage renal failure (n ¼ 1), and un-
known cause but without disease within 3 months of death (n¼ 4).
The estimated 5-year overall survival for the entire population was
52% [95% conﬁdence interval (CI), 41e62%; Fig. 1].
Speciﬁc to GU tract malignancies, 29 patients experienced dis-
ease recurrence, including 19 felt to be true recurrence of bladderTable 1
Patient demographic and preoperative tumor, staging, and work-up data.
Variable RCP (n ¼ 94)
N (%)
Age
Median 70
(Range) (41e85)
 75 y 29 (31)
Race
Caucasian 92 (98)
Prior urothelial cancer? 42 (45)
Median times recurrent 2
(Range) (1e8)
Bladder clinical stage
cTis/Ta (0) 8 (9)
cT1N0 (I) 19 (20)
cT2N0 (II) 59 (63)
cT3N0 (III) 2 (2)
cT4aN0 (III) 3 (3)
cNþ (IV) 3 (3)
Pelvis staging studies
CT 87 (93)
MRI 4 (4)
PET 2 (2)
None 2 (2)
Thoracic staging studies
Chest X-ray 77 (82)
Chest CT 15 (16)
PET 0 (0)
None 2 (2)
Osseous staging
Bone scan 27 (29)
PET 2 (2)
Bone scan þ PET 1 (1)
None 64 (68)
PSA
Performed < 1 y preRCP 25 (27)
Median 2.0 ng/mL
(Range) (0.2e8.6)
> 4.0 7 (7)
Note. Data in the “Bladder clinical stage” section as per “AJCC Cancer Staging
Manual,” by Edge, S., et al, 2010, 7th Edition. Copyright 2011, Springer
ScienceþBusiness Media, LLC.
CT, computed tomography; MRI, magnetic resonance imaging; PET, positron
emission tomography; PSA, prostate speciﬁc antigen; RCP, radical
cystoprostatectomy.cancer, another nine new GU tract primary tumors, and one inde-
terminate (lost to clinical follow-up, records report “metastatic
bladder cancer” as cause of death). Six of these patients were suc-
cessfully salvaged, primarily with resection (n ¼ 3), intraureteral
therapy (n¼ 2), or both (n¼ 1). All but two of these patients remain
alive, without evidence of disease, with the remaining patients
dying of unknown cause (without clinical or radiographic evidence
of active disease at follow-up 3 months and 6.5 months prior to
death, respectively). An additional patient was known to have
disease recurrence, with salvage treatment elsewhere, having later
died of indeterminate cause (scored as “died unknown cause,”
owing to 15-month lapse between previous record and death).
Patterns of GU disease failure are demonstrated in Table 3.
The estimated 5-year DFS for bladder and GU tract cancers were
76% (65e84%; Fig. 2) and 64% (52e74%; Fig. 3), respectively. The
estimated GU tract malignancy DSS was 61% (49e71%; Fig. 4).
Univariate analysis of factors associated with GU tract malig-
nancy DFS demonstrated statistically signiﬁcant association with
recurrent disease at the time of RCP (vs. initial presentation of
bladder pathology; Table 4). Univariate analysis of factors associ-
ated with GU tract malignancy DSS demonstrated statistically sig-
niﬁcant associations with pathologic T- and N-stage; upon
multivariate analysis, only pathologic N-stage was independently
associated with GU tract malignancy-speciﬁc mortality.
Speciﬁc to prostate cancer, the majority of patients had
Gleason < 6 with negative surgical margins (n ¼ 61; 65%).
Additional pathologic data are characterized in Table 5. Of note,
31 patients (33%) had characteristics of “clinically signiﬁcant”
tumors, including seven with positive margin (all but 2 patients
of which were Gleason > 6). No patient had seminal vesicleTable 2
Bladder cancer-speciﬁc pathologic data.
Variable RCP
(n ¼ 94)
N (%)
Interval biopsy to RCP a)
Median interval 48 d
(Range) (7e224)
> 100 d 3 (3)
Specimen volume
Median 390 g
(Range) (230e1,850)
Pathologic T-stage a)
pTa 2 (2)
pTis 3 (4)
pT1 9 (11)
pT2 28 (33)
pT3 33 (39)
pT4 9 (11)
Pathologic N-stage a)
pN0 62 (73)
pN1 9 (11)
pN2 11 (13)
pN3 3 (4)
Pathology ﬁndings
Perineural invasion b) 28 (35)
Lymphovascular invasion b) 42 (51)
Involved margin(s) 9 (10)
Involved LN(s) 42 (51)
a) Excludes nine patients who underwent preoperative chemotherapy; staging as
per “AJCC Cancer Staging Manual,” by Edge, S., et al, 2010, 7th Edition, Copyright
2011, Springer ScienceþBusiness Media, LLC. One patient each experienced biopsy to
RCP interval > 100 days for: intravesicle gemcitabine/mitomycin C toxicity (224
days), intravesicle bCG-associated toxicity (126 days), and patient-associated
scheduling delay (102 days).
b) Excludes 14 patients and 11 patients without recorded perineural and lym-
phovascular invasion data, respectively.
LN, lymph nodes; RCP, radical cystoprostatectomy.
Fig. 2. Bladder cancer-speciﬁc disease-free survival.
Fig. 3. Urinary tract malignancy-speciﬁc disease-free survival.
Fig. 1. Overall survival for the study population.
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had initial surveillance PSA performed within 1 year postRCP, all
of which were  0.05 ng/mL. At a median PSA follow-up of 29.8
months (3.0e147.2, with 29% at  5 years), only one patient had
experienced PSA relapse, involving an initial rise to 0.30 at 44.7
months postRCP, with very gradual subsequent rise to 0.41 (PSA
doubling time 183.5 months; no intervention performed). It is
noteworthy that this patient did not have any “clinically signiﬁ-
cant” pathologic features (pT2aN0, Gleason 3 þ 3 ¼ 6, without
extraprostatic extension, seminal vesicle invasion, or positive
margin). Additionally, six patients had minimal detectable
postRCP PSA elevation to  0.1, were followed without inter-
vention, and were thus not scored as PSA relapses. The estimated
5-year PSA relapse-free survival for the population was 97%
(79e100%; Fig. 5). No patient experienced symptomatic recur-
rence of prostate cancer, nor did any undergo salvage interven-
tion for PSA rise or recurrence.
4. Discussion
In many industrialized nations, including the United States,
prostate cancer is the most common cancer in males.1 Although the
value of physical examination and serologic screening methods for
prostate cancer remains controversial,4 the fact remains that many
men diagnosedwith clinically localized diseasewill die with, rather
than of, prostate cancer, irrespective of intervention.5 Autopsy se-
ries have conﬁrmed high rates of incidental prostate cancers, with
the majority of men having survived without formal diagnosis of
malignancy.6 Speciﬁc to patients undergoing RCP, the reported
rates of incidental prostate cancers are 14e50%,3,7e11 which aligns
well with our own experience (34%). Likely, differences in patho-
logic processing technique play a role in the variable reportedTable 3
Patterns of genitourinary tract malignancy failure for patients with radical cys-
toprostatectomy performed for bladder cancer, with incidental prostate cancer
identiﬁed in pathologic specimen.
n (%) a)
Local only 1 (1)
Regional nodal only 1 (1)
Locoregional þ distant 3 (3)
Distant only 14 (15)
Nonbladder GU tract 9 (10)
Unknown 1 (1)
a) Denominator excludes three patients with treatment-associated mortality.
GU, genitourinary.
Fig. 4. Urinary tract malignancy disease-speciﬁc survival.incidence, with more meticulous sampling (e.g., 2e3 mm step-
sectioning of whole-mount specimen) responsible for increased
detection.12 This is further suggested by higher relative rates of
“clinically insigniﬁcant” disease in series with higher detection
rates.3,7 There does remain some debate concerning the high
Table 4
Univariate analyses of variable association with genitourinary tract malignancy-
speciﬁc disease-free survival (DFS) and disease-speciﬁc survival (DSS).
DFS DSS
HR
(95% CI)
P HR
(95% CI)
P
Age (units ¼ 1) 1.02
(0.98e1.06)
0.38 1.03
(0.99e1.06)
0.16
Interval biopsy to surgery
(units ¼ 1)
1.01
(0.99e1.02)
0.39 0.99
(0.98e1.01)
0.41
Prior urothelial cancer 2.16
(1.02e4.58)
0.04 1.32
(0.68e2.55)
0.42
Clinical stage 0.63
(0.30e1.31)
0.21 1.17
(0.56e2.44)
0.68
Preoperative chemotherapy 1.17
(0.35e3.89)
0.79 1.08
(0.38e3.09)
0.89
Bladder pT-stage a) 1.50
(0.69e3.25)
0.30 2.44
(1.17e5.12)
0.02
Bladder pN-stage a) 1.87
(0.80e4.37)
0.15 3.11
(1.51e6.43)
< 0.01
Nodal ratio a) 1.04
(0.28e3.91)
0.95 1.32
(0.45e3.86)
0.61
Bladder margin 0.77
(0.18e3.27)
0.73 1.05
(0.32e3.43)
0.94
Bladder perineural invasion 1.11
(0.49e2.51)
0.81 0.85
(0.40e1.79)
0.66
Postoperative chemotherapy 0.89
(0.27e2.96)
0.85 1.08
(0.38e3.09)
0.88
Note. Data in the “clinical stage”, “Bladder pT-stage”, and “Bladder pN-stage”, sec-
tions as per “AJCC Cancer Staging Manual,” by Edge, S., et al, 2010, 7th Edition.
Copyright 2011, Springer ScienceþBusiness Media, LLC.
Statistically signiﬁcant ﬁndings identiﬁed in bolded font.
a) For purposes of univariate analysis, clinical stage dichotomized to 0eI versus
IIeIV, bladder pT stage dichotomized to 0e2 versus 3e4, bladder N-stage dichoto-
mized to 0 versus 1e3, and nodal ratio to 20% versus < 20% (with only Nþ patients
included).
CI, conﬁdence interval; HR, hazard ratio (for dichotomized data).
Table 5
Prostate cancer-speciﬁc pathologic data.
Variable N (%)
Gleason score at RCP
4 3 (3)
5 4 (4)
6 58 (62)
7 28 (30)
8 0 (0)
9 1 (1)
Pathologic T-stage
pT2a 46 (49)
pT2b 5 (5)
pT2c 40 (43)
pT3a 3 (3)
Pathology ﬁndings
Perineural invasion b) 28 (35)
Lymphovascular invasion b) 42 (51)
Extraprostatic extension 5 (5)
Involved seminal vesicle (s) 0 (0)
Involved margin (s) 7 (7)
Involved LN (s) 0 (0)
Clinically Signiﬁcantc) 31 (33)
Note. Data in the “clinical stage”, “Bladder pT-stage”, and “Bladder pN-stage”, sec-
tions as per “AJCC Cancer Staging Manual,” by Edge, S., et al, 2010, 7th Edition.
Copyright 2011, Springer ScienceþBusiness Media, LLC.
a) Delayed RCP due to preoperative chemotherapy.
b) Excludes 13 and 24 patients without recorded perineural and lymphovascular
invasion data, respectively.
c) Deﬁned as seminal vesicle invasion, positive surgical margins, pathologic
Gleason Score > 6, or pelvic lymph node involvement.
LN, lymph node(s); RCP, radical cystoprostatectomy.
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pathway;2 however, this remains speculative, and further investi-
gation is required. Investigators from the Polytechnic University of
the Marche Region in Italy suggest incidental prostate cancers are
biologically less aggressive.8,13 Whether this is inherent to a pop-
ulation of patients with synchronous bladder cancer or merely an
early representation of the natural history of prostate cancer re-
mains to be determined.
Within the literature speciﬁc to incidentally-identiﬁed prostate
cancers, the term “clinically signiﬁcant” has been routinely applied,
employing factors such as: seminal vesicle invasion, positive sur-
gical margins, pathologic Gleason Score > 6, pelvic lymph node
involvement, or tumor volume > 0.5 cc.2 Prior series of incidental
prostate cancers identiﬁed at RCP have described low rates of
biochemical relapse (< 5%) and prostate-cancer speciﬁc mortality
(0%), irrespective of this terminology.3,9e11 Speciﬁc to our popula-
tion, 31 patients had “clinically signiﬁcant” pathologic features,
none of whom experienced PSA failure. As only one patient had
very gradual PSA rise unlikely to be associated with prostate
cancer-speciﬁc mortality (PSA doubling time of 183 months),14 and
no patient experienced symptomatic recurrence of prostate cancer,
use of the term “clinically signiﬁcant” would seem inaccurate, at
least with respect to prostate cancers diagnosed incidentally at RCP
for muscle-invasive bladder cancer. It is noteworthy that we did not
report on volume of prostate carcinoma (with < 0.5 cc vs. > 0.5 cc as
determinant), as this data point was not prospectively recorded.
In terms of prostate cancer surveillance in this setting, as the
bladder cancer diagnosis warranting RCP demonstrates the more
aggressive pathologic process, it would seem prudent to perform
initial postRCP PSA within 1e3 months postoperatively, following
annually thereafter, in the absence of highly aggressive features(e.g., Gleason 8e10, pelvic nodal or seminal vesicle involvement,
multifocal or large extent of positive margin).2 Adjuvant hormone
or radiation therapy does not appear warranted in this setting,
speciﬁc to the prostate cancer diagnosis.
Speciﬁc to bladder cancer, the 5-year disease control and survival
rates for the present series compare well with prior incidental
prostate cancer series3 as well as those of trial participants.15 This
would suggest that bladder carcinoma in the setting of concomitant
prostate cancerdoes not behavemore aggressively, and ismost likely
to be coincidental rather than correlated. Although one small series
demonstrated poorer outcome for postRCP bladder cancer patients
with incidental prostate cancers (as compared with those without
prostate cancer),16 our data, constituting the second largest report to
date, do not appear to support this. Similarly, in the largest published
series on this topic, investigators at the University of Southern Cali-
fornia did not demonstrate differences in survival between RCP-
managed bladder cancer patients with and without incidental
prostate adenocarcinoma.3 In this series, which included 1,476 pa-
tients who underwent RCP between 1970 and 2008 for urothelial
carcinoma of the bladder (without prior known history of prostate
cancer), 559 patients (38%) were identiﬁed to have incidental pros-
tate adenocarcinoma (n ¼ 123 “clinically signiﬁcant”). Of note,
prostatic stromal invasion by urothelial carcinomawas signiﬁcantly
associatedwithworse 10-year overall survival (22%) than superﬁcial
prostatic urethral/duct (43%) or no prostatic involvement (47%).
A weakness of the present investigation is the limited data on
bladder cancer disease-speciﬁc survival, primarily owing to 17 pa-
tients whose death occurred > 3 months from their previous
recurrence-free clinical follow-up. Although unfortunate, this was
anticipated, primarily owing to patients’ long-distance travel to our
tertiary referral center. As such, patients were frequently referred
back to their local community urologist after 3e5 years of follow-
up, or sooner upon patient preference, with variable continued
correspondence.
Within the present investigation, the predominant patterns of
failure were distant recurrences and new GU tract primaries (28 of
Fig. 5. PSA relapse-free survival. PSA ¼ prostate speciﬁc antigen.
Prostate Int 4 (2016) 107e11211230 recurrences with documented failure site), with only two
locoregional-only failures. This is similar to prior series on this
topic,3 and muscle-invasive bladder cancer generally.1 Given the
low utilization of pre- and postoperative chemotherapy in our se-
ries, the distant pattern of failure would suggest potential for
improvement. Randomized trials of pre- and postoperative
chemotherapy have demonstrated improved cancer control and
survival for bladder cancer patients who undergo RCP for bladder
cancer.13,17e19 Whether this effect is preserved in patients with
synchronous prostate cancers remains to be determined. With
respect to locoregional control, Although limited data suggest an
opportunity for pelvis-directed radiotherapy to improve pelvic
disease control (particularly in the setting of involved margins),20
the infrequency of such failures in our study population limits
our ability to comment further.
Our investigation identiﬁed statistically signiﬁcant associations
between lymph node ratio and GU tract-speciﬁc and overall sur-
vivals. Given the distant pattern of failure, it appears that increasing
nodal burden reﬂects a higher probability of occult metastatic dis-
ease, as this factor has been previously reported as independently
associated with disease control and survival.21 Whether patients
may experience differential beneﬁt of adjuvant chemotherapywhen
speciﬁcally stratiﬁed by nodal ratio remains to be determined.5. Conclusion
Incidental prostate cancer identiﬁed at RCP for urothelial bladder
cancer appears to have little impact on the natural history of disease,
with GU tract malignancy-related recurrence and mortality domi-
nating as the most common pattern. In long-term bladder cancer
survivors, the intermediate-term PSA relapse rate appears to be very
low, irrespective of “clinically signiﬁcant” features.Conﬂicts of interest
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